Skip to content

A preliminary study tracking adults with rheumatoid arthritis to correlate how their symptoms, blood tests, and joint scans can predict which standard arthritis medications will work best for them.

Clinical, Laboratory, and Imaging Parameters Associated with Differential Responsiveness to Disease-Modifying Antirheumatic Drugs (DMARDs) in Adults with Rheumatoid Arthritis: A Pilot Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112218
Enrollment
20
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement

Interventions

Intervention1: Nil: Nil

Sponsors

BANGALORE BAPTIST HOSPITAL BANGALORE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adults (18-85 years) presenting to the Rheumatology and Medicine department of BBH and CRICR institute with a new diagnosis of rheumatoid arthritis. All patients with a new or previous diagnosis of Rheumatoid arthritis who have discontinued conventional or biologic DMARDs for more than three months, with the exception of Leflunomide (as its metabolites remain for up to two years)

Exclusion criteria

Exclusion criteria: 1-Patients treated with DMARDs or steroids for more than 1 month 2-Mixed connective tissue disease (MCTD) and other overlap connective tissue diseases with RA component 3-Patients with acute or chronic viral infections like Hepatitis C, HIV or Hepatitis B that preclude the use of conventional and biological DMARDS 4-Patients who experience significant adverse drug events that necessitate discontinuation of the DMARDs during the treatment will be excluded at any point during the study 5-Age above 85 years due to higher risks of infection and other adverse effects with higher doses of Methotrexate or biologic agents for non - responders to conventional DMARDs. 6-Diagnosis of concomitant Interstitial Lung Disease (ILD) complicating Rheumatoid Arthritis. 7-Organ dysfunction: Renal failure- CKD Stage G3 and higher ( Creatinine clearance less than 60 ml/mt). Baseline deranged liver function and chronic liver disease of any aetiology (ethanol abuse or non-alcoholic fatty liver disease - NAFLD or metabolic dysfunction-associated fatty liver disease MAFLD

Design outcomes

Primary

MeasureTime frame
Preliminary estimates of response and non-response rates Timepoint: Response to treatment with conventional DMARDS at the end 3 months

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactJACOB MATHEWS VAHANEYIL

BANGALORE BAPTIST HOSPITAL

jacobmathews@bbh.org.in08022024700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026